TABLE OF CONTENTS

4 OVERVIEW

4 Drug Overview

5 Product Profiles

5 Breo Ellipta : Chronic obstructive pulmonary disease (COPD)

25 Breo Ellipta : Asthma

LIST OF FIGURES
17 Figure 1: Breo for COPD - SWOT analysis

18 Figure 2: Datamonitor Healthcare's drug assessment summary of Breo for COPD

19 Figure 3: Datamonitor Healthcare's drug assessment summary of Breo for COPD

21 Figure 4: Breo sales for COPD across the US, Japan, and five major EU markets, by country, 2017-26

33 Figure 5: Breo Ellipta for asthma - SWOT analysis

34 Figure 6: Datamonitor Healthcare's drug assessment summary of Breo Ellipta in asthma

35 Figure 7: Datamonitor Healthcare's drug assessment summary of Breo Ellipta in asthma

37 Figure 8: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

LIST OF TABLES
6 Table 1: Breo drug profile

7 Table 2: Breo Phase III data in COPD

12 Table 3: Breo Phase III trials in COPD

22 Table 4: Breo sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017-26

25 Table 5: Breo Ellipta drug profile

27 Table 6: Breo Ellipta pivotal trial data in asthma

30 Table 7: Breo Ellipta late-phase trial data in asthma
38 Table 8: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26